

---

**Product Data Sheet**


---

Product Name: INCB 3284 dimesylate

Cat. No.: GC14821

**Chemical Properties**

Cas. No. 887401-93-6

Chemical Name N-(2-((1-(4-hydroxy-4-(6-methoxypyridin-3-yl)cyclohexyl)pyrrolidin-3-yl)amino)-2-oxoethyl)-3-(trifluoromethyl)benzamide dimethanesulfonate

SMILES COC1=NC=C(C2(O)CCC(N3CCC(NC(CNC(C4=CC(C(F)(F)F)=CC=C4)=O)=O)C3)CC2)C=C1.CS(=O)(O)=O.CS(=O)(O)=OFormula C<sub>28</sub>H<sub>39</sub>F<sub>3</sub>N<sub>4</sub>O<sub>10</sub>S<sub>2</sub> M.Wt 712.76

Solubility DMF: 11 mg/ml, DMSO: 12 mg/ml, PBS (pH 7.2): 5 mg/ml Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure **Protocol****Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

### Animal experiment:

Mice[2]Male C57Bl/6 mice (20 to 25 g) are given free access to water and rodent chow and are housed in constant temperature, humidity, and 12 h light-dark cycling. Acute liver failure is induced via a single intraperitoneal (ip) injection of 100 mg/kg of azoxymethane (AOM). In parallel, systemic inhibition of CCR2 and CCR4 activity is accomplished via pretreatment with INCB 3284 (1 mg/kg/day ip) or C021 (1 mg/kg/day ip) for 3 days prior to injection of AOM. Following injection, mice are placed on heating pads adjusted to 37°C and monitored frequently for signs of neurological decline. To reduce the impacts of hypoglycemia and dehydration, cage floors are supplied with hydrogel and rodent chow and after 12 h, and every subsequent 4 h, mice are injected subcutaneously with 5% dextrose in 250 µL of saline. If mice undergo a 20% or greater weight loss they are removed from the study[2].

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

### References:

- [1]. Xue CB, et al.  
Discovery of  
INCB3284, a  
Potent, Selective,  
and Orally  
Bioavailable hCCR2  
Antagonist. ACS  
Med Chem Lett.  
2011 Mar  
31;2(6):450-4.
- [2]. McMillin M, et  
al. Neuronal CCL2  
is upregulated  
during hepatic  
encephalopathy  
and contributes to  
microglia activation  
and neurological  
decline. J  
Neuroinflammation.  
2014 Jul 10;11:121.

### Background

INCB 3284 dimesylate is a potent, selective and orally bioavailable human CCR2 antagonist, inhibiting monocyte chemoattractant protein-1 binding to hCCR2, with an IC<sub>50</sub> of 3.7 nM. INCB 3284 dimesylate can be used in the research of acute liver failure.

INCB 3284 dimesylate is a potent, selective and orally bioavailable human CCR2 antagonist, inhibiting monocyte chemoattractant protein-1 binding to hCCR2, with an IC<sub>50</sub> of 3.7 nM. INCB 3284 also causes an IC<sub>50</sub> of 4.7 nM in antagonism of chemotaxis activity, an IC<sub>50</sub> of 84 μM in inhibition of the hERG potassium current. However, INCB 3284 has no effect on CCR1, CCR3, CCR5, CXCR3, and CXCR5, or additional GPCRs at a

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

concentration of 1  $\mu$ M. Moreover, INCB 3284 potently inhibits CCR2-mediated signaling events such as intracellular calcium mobilization and ERK phosphorylation with IC<sub>50</sub> values of 6 and 2.6 nM, respectively[1].

INCB 3284 (1 mg/kg/day, ip) reduces liver damage, and decreases microglia activation in AOM-treated mice via inhibition on CCR2. INCB 3284 also significantly reduces the pERK1/2 to tERK1/2 ratio, as well as G-protein signaling pathway activity and proinflammatory cytokine production in cortex lysates from mice administered with azoxymethane[2].

### References:

- [1]. Xue CB, et al. Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist. ACS Med Chem Lett. 2011 Mar 31;2(6):450-4.
- [2]. McMillin M, et al. Neuronal CCL2 is upregulated during hepatic encephalopathy and contributes to microglia activation and neurological decline. J Neuroinflammation. 2014 Jul 10;11:121.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA